Biotechnology News 8 January 2026

Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

New York, Jan 11, 2026, 08:22 EST — Market closed. Regencell Bioscience Holdings Ltd shares closed Friday up 10.6% at $45.79, recovering sharply after dipping roughly 15% during the session. The Nasdaq-listed stock kicked off the day at $36.08 and

11 January 2026

Biotechnology·Financial News·Investing·Stock Market·Trading

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

New York, January 10, 2026, 21:25 EST — Market closed Shares of Wave Life Sciences Ltd dropped 6.7% on Friday, ending the day at $13.84. The stock swung between a high of $15.09 and a low of $13.76 during the

11 January 2026

Biotechnology·Financial Analysis·Healthcare·Investment News·Stock Market

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

New York, January 10, 2026, 19:54 EST — The market has closed. CG Oncology Inc (CGON) shares surged nearly 29% on Friday, closing at $54.20 after hitting a session high of $57.36. The stock gained $12.25 during the day on

11 January 2026

Biotechnology·Cancer Research·Clinical Trials·Pharma News·Stock Market

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

NEW YORK, Jan 10, 2026, 08:12 (EST) Schrödinger announced it will integrate Eli Lilly’s TuneLab, an AI-driven drug discovery platform, into its LiveDesign software. This move offers biotech teams direct access to Lilly’s predictive models. “LiveDesign will be a priority

10 January 2026

Artificial Intelligence·Biotechnology

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

New York, Jan 9, 2026, 15:11 EST — Regular session CRISPR Therapeutics AG shares slid on Friday, bucking a firmer broader market, after a regulatory filing flagged a chief financial officer’s share sale under a pre-arranged trading plan. (Reuters) The

9 January 2026

Biotechnology·Business News·Pharmaceuticals·Stock Market

Why Regencell Bioscience (RGC) stock is moving today: choppy rebound after Nasdaq pauses

NEW YORK, Jan 9, 2026, 12:43 EST — Regular session Regencell Bioscience Holdings Limited shares rose about 8.5% to $44.96 in midday trading on Friday, clawing back from an early dip. The stock has swung between $35.13 and $50.92 in

9 January 2026

Biotechnology·Financial Updates·Investment Analysis·Stock Market

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

New York, Jan 9, 2026, 11:52 EST — Regular session CG Oncology shares jumped on Friday after the company moved up the expected timing for late-stage trial results in bladder cancer. The stock was up 25.1% at $52.45 by 11:52

9 January 2026

Biotechnology·Clinical Trials·Pharmaceutical News·Stock Market

Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

New York, Jan 9, 2026, 11:27 EST — Regular trading Eli Lilly and Company (LLY) shares were down about 0.4% at $1,081 in morning trade on Friday. The drugmaker said this week it will buy autoimmune developer Ventyx Biosciences for

9 January 2026

Biotechnology·Business News·Investments·Pharmaceuticals·Stock Market

MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

New York, Jan 8, 2026, 17:06 EST — After-hours MoonLake Immunotherapeutics shares jumped 27% to $14.34 on Thursday after the biotech said U.S. regulators supported a route to file its hidradenitis suppurativa treatment without doing more trials for the skin

8 January 2026

Biotechnology·Clinical Trials·FDA Approvals·Pharmaceuticals·Stock Market

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

New York, Jan 8, 2026, 13:46 EST — Regular session Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as

8 January 2026

Biotechnology·Company News·Investments·Pharmaceuticals·Stock Market

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed

8 January 2026

Biotechnology·Cancer Research·Investment·Pharmaceutical News·Stock Market

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price

8 January 2026

Biotechnology·Financial Analysis·Investments·Pharma News·Stock Market

Biotechnology News 8 January 2026 - 11 January 2026